Orbital® Dry Powder Inhaler

Orbital Dry Powder Inhaler (DPI) convenient delivery of high drug doses to the lungs.

Orbital multi use

The Orbital technology is built on Pharmaxis patents, which allow powder payloads of up to 400mg or more to be inhaled by patients in divided doses without the need to reload.  This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol®(mannitol). However, it also meets an increasing global need to deliver high doses of other drugs, such as antibiotics, to the lungs.  

The Orbital Inhaler is an innovative device that eliminates the need for manual reloading of multiple powder-containing capsules needed for a single dose of drug.  This can deliver improvements in the patient experience, compliance, market share and also effectively extend patent life of drugs that use the device.  The prototype developed by Pharmaxis has been tested in phase 1 studies where it performed well.

Status

In August 2021 Pharmaxis and drug delivery solutions provider Aptar Pharma announced  they had entered into an agreement under which Aptar Pharma obtained an option to acquire the worldwide rights to Pharmaxis’ proprietary inhaler Orbital.

As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Aptar will pay Pharmaxis US$250k for the 12-month option and a further US$2.5m on exercise of the option.  If exercised, Aptar will pay Pharmaxis industry standard royalties on income received for Orbital.  Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol. Read more here.

Earlier, in November 2016 Pharmaxis announced a research collaboration with Sydney’s prestigious Woolcock Institute of Medical Research to develop a novel inhalation therapy for the treatment of cystic fibrosis (CF). The project brings together the acknowledged expertise of the Woolcock Institute and Pharmaxis in the field of cystic fibrosis. The ability to deliver antibiotics locally, using the Orbital device overcomes a number of challenges that are experienced in the clinic, and the clinical trial is likely to pave the way to better health outcomes and quality of life. The National Health and Medical Research Council (NHMRC) has awarded a research grant in support of the research collaboration.